Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Cancer
Chemotherapy and HAART feasible for HIV-NHL patients
April 6th, 2004
Simultaneous chemotherapy and HAART regimens are feasible for HIV patients with non-Hodgkin lymphoma. Researchers in Italy "evaluated replication of human immunodeficiency virus (HIV) and the genotypic resistance pattern in 26 HIV-infected patients affected by non-Hodgkin lymphoma who were treated with at least three cycles of chemotherapy (CT; rituximab and CDE) and highly active antiretroviral therapy (HAART)." "Genotyping was performed at baseline and when virological failure occurred. Six patients met the virological failure criteria," noted C. Simonelli and coauthors at the Istituto Nazionale Tumori in Aviano. "The genotyping...
Source: Cancer Weekly (2004-04-06)
|
